

# HOW DO YOU ASSESS EARLY SIGNS OF RESISTANCE?

Quinn is a mother of 3 and is constantly in motion. She wants to get back to her active lifestyle.

<b>Sokal risk score</b>	Intermediate risk (1.2)
<b>Current treatment</b>	2nd-line TKI
<b>Length of time on current treatment</b>	3 months
<b>Molecular status</b>	<b>15% BCR-ABL1</b>

- Quinn is showing early signs of potential resistance to her current treatment. How would you assess a patient like Quinn to evaluate if her CML is under control?
- According to National Comprehensive Cancer Network® (NCCN®), patients with >10% BCR-ABL1 at 3 months have possible TKI resistance

LEARN ABOUT UNMET NEEDS IN CML. [VISIT OUR SITE](#)

**TARGETCML**

CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia V.3.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed March, 20, 2021. To view the most recent and complete version of the guideline, go online to [NCCN.org](https://www.nccn.org). NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.



Novartis Pharmaceuticals Corporation  
East Hanover, New Jersey 07936-1080

© 2021 Novartis

3/21

110589

